CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
2023年10月17日 - 8:00PM
ビジネスワイヤ(英語)
Demonstrates Breadth of Offerings for HLA
Laboratories and Validation of AlloSeq HCT
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on
the discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers – today announced a leading presence at the
49th annual meeting of the American Society for Histocompatibility
and Immunogenetics (ASHI) being held in San Antonio, Texas from
October 16-20, 2023.
The latest advances across CareDx’s portfolio of HLA typing
solutions and AlloSeq HCT for use in hematopoietic stem cell
monitoring1 are being showcased across nineteen abstracts and two
company-sponsored symposia. These peer-reviewed abstracts
demonstrate the scientific validation and utility of CareDx
products and solutions.
“CareDx is proud to be a leading sponsor of this year’s ASHI
meeting and driving continued innovation in transplantation with
our best-in-class portfolio of HLA typing and workflow solutions,”
said Reg Seeto, CEO and President of CareDx. “We are also excited
to share the latest update on AlloSeq HCT, a transformative
solution for chimerism monitoring in patients undergoing
hematopoietic stem cell transplantation.”1
For HLA laboratories, CareDx offers NGS-based typing solutions
with AlloSeq Tx,1 QTYPE,1 SSP, and mTilda LIMS (Laboratory
Information Management System). AlloSeq Tx171 delivers a novel
method for matching transplant recipients and potential donors. The
hybrid capture approach to matching is unique to CareDx and gives
labs flexibility in gene content and increased robustness over
other methodologies. mTilda LIMS software, virtual crossmatch, and
epitope analysis are designed to improve transplant outcomes. For
allogeneic hematopoietic stem cell transplant (allo-HCT)
monitoring, AlloSeq HCT1 offers a streamlined and sensitive
approach for NGS-based engraftment monitoring and surveillance
following allo-HCT.
CareDx will host two symposia focused on “Innovation Across the
Pre- and Post-Transplant Journey”:
Tuesday, October 17, moderated by Hal Gibson, Senior Vice
President, Strategic Partnering, CareDx:
- The History of Donor-Derived cfDNA in Transplantation.
Robert Woodward, PhD, Chief Scientific Officer, CareDx.
- Evolving Clinical Utility of Donor-Derived Cell-DNA for
Post-Transplant Management. Gaurav Gupta, MD, Professor of
Medicine and Surgery, Interim Chief, VCU Division of Nephrology,
Medical Director of Kidney/Pancreas Transplantation, Hume-Lee
Transplant Center.
- Elevating the Standard of Care in Transplant Surveillance:
Integrating Non-Invasive Biomarkers with Clinical Parameters.
Carmen Lefaucheur, MD, Head of the Department of Nephrology and
Kidney Transplantation, Saint-Louis Hospital-APHP, Paris, France,
and Professor of Nephrology at Université Paris Cité, Medical
Director of the Paris Institute for Transplantation & Organ
Regeneration, Director of the Research FHU Apollo.
Wednesday, October 18, moderated by Curtis Lind, Vice President,
Head of R&D, Products, CareDx, and Michael Reardon, Senior
Director, HLA Software Portfolio, CareDx:
- Latest Advances in AlloSeq Products & Software.
Beata Kmiec, PhD, Product Manager, CareDx.
- Revolutionizing Chimerism Analysis: Harnessing the Power of
NGS and SNP Panels for Superior Results. Ahmed Mostafa, MD,
PhD, Director, Technical Supervisor, and Clinical Consultant,
Histocompatibility and Immunogenetics Laboratory, St. Paul's
Hospital—Saskatoon.
- Virtual Crossmatching and Epitope Analysis as Informational
Aids in the Transplant Decision Making Process: A Review of VXMatch
and VECTR. Eszter Lazar-Molnar, PhD, D(ABMLI), F(ACHI),
Assistant Professor Department of Pathology, University of
Utah.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the potential
benefits and results that may be achieved with CareDx’s leading
presence and sponsorship in 2023 ASHI meeting (the “Meeting”),
AlloSeq HCT and its HLA typing solutions, and its presentation of
the latest data on AlloSeq HCT and HLA typing solutions at the
Meeting (the “Presentation”). These forward-looking statements are
based upon information that is currently available to CareDx and
its current expectations, speak only as of the date hereof, and are
subject to risks and uncertainties that could cause actual results
to differ materially from those projected, including risks that
CareDx does not realize the expected benefits of its leading
presence and sponsorship in the Meeting, AlloSeq HCT or its HLA
typing solutions, or its Presentation; general economic and market
factors; and other risks discussed in CareDx’s filings with the
SEC, including the Annual Report on Form 10-K for the fiscal year
ended December 31, 2022 filed by CareDx with the SEC on February
27, 2023, the quarterly report on Form 10-Q for the quarter ended
March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the
quarterly report on Form 10-Q for the quarter ended June 30, 2023
filed by CareDx with the SEC on August 8, 2023, and other reports
that CareDx has filed with the SEC. Any of these may cause CareDx’s
actual results, performance, or achievements to differ materially
and adversely from those anticipated or implied by CareDx’s
forward-looking statements. CareDx expressly disclaims any
obligation, except as required by law, or undertaking to update or
revise any such forward-looking statements.
References
1. AlloSeq Tx17, AlloSeq HCT, and QTYPE are for research use
only in the United States.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017412903/en/
CareDx, Inc.
Media Relations Anna Czene 818-731-2203 aczene@caredx.com
Investor Relations Greg Chodaczek Investor@caredx.com
CareDx (NASDAQ:CDNA)
過去 株価チャート
から 4 2024 まで 5 2024
CareDx (NASDAQ:CDNA)
過去 株価チャート
から 5 2023 まで 5 2024